11 research outputs found
Spearman rank correlation for serum VEGF-A concentration [pg/ml] before surgery and histological character of the tumor.
<p>Spearman rank correlation for serum VEGF-A concentration [pg/ml] before surgery and histological character of the tumor.</p
Spearman rank correlation for serum VEGF-A [pg/ml] before surgery and after surgery.
<p>Spearman rank correlation for serum VEGF-A [pg/ml] before surgery and after surgery.</p
Descriptive statistics—Serum VEGF-A [pg/ml] concentrations before surgery, depending on the tumor type.
<p>Descriptive statistics—Serum VEGF-A [pg/ml] concentrations before surgery, depending on the tumor type.</p
Mann-Whitney U test of differences between the study and the comparison group.
<p>Mann-Whitney U test of differences between the study and the comparison group.</p
Distribution of serum VEGF-A [pg/ml] before surgery due to the type of tumor.
<p>Distribution of serum VEGF-A [pg/ml] before surgery due to the type of tumor.</p
Kruskal-Wallis ANOVA rank for serum VEGF-A concentration [pg/ml] before surgery and tumor type, Kruskal-Wallis test: H (3, N = 48) = 1.047748 p = .7897.
<p>Kruskal-Wallis ANOVA rank for serum VEGF-A concentration [pg/ml] before surgery and tumor type, Kruskal-Wallis test: H (3, N = 48) = 1.047748 p = .7897.</p
Descriptive statistics of tested variables—Serum VEGF-A in the study and comparative group.
<p>Descriptive statistics of tested variables—Serum VEGF-A in the study and comparative group.</p
Bioavailability of ticagrelor and AR-C124910XX over time in patients with STEMI and NSTEMI.
<p>Plasma concentrations of (A) ticagrelor and (B) AR-C124910XX during the first 6 h after oral administration of a 180 mg ticagrelor loading dose in patients with STEMI and NSTEMI. NSTEMI: non-ST-elevation myocardial infarction, STEMI: ST-elevation myocardial infarction.</p
Prevalence of high platelet reactivity over time in STEMI and NSTEMI patients.
<p>Proportion of patients with high platelet reactivity assessed with (A) the VASP assay and Multiplate (B) at baseline, and at 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, and 12 h after administration of a 180 mg ticagrelor loading dose in patients with STEMI and NSTEMI. HPR: high platelet reactivity, NSTEMI: non-ST-elevation myocardial infarction, STEMI: ST-elevation myocardial infarction, VASP: vasodilator-stimulated phosphoprotein.</p
Baseline characteristics of study participants.
<p>Baseline characteristics of study participants.</p